[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQAFmwrQDLTBeqMog60ouqhB58WUyXOysqvNCeQj-SuA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Catholic University of the Sacred Heart",[4],234,false,23,13,76794,2,176,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Polycystic Ovary Syndrome",11,{"name":18,"count":19},"Obesity",9,{"name":21,"count":22},"Developmental Dyslexia",5,{"name":24,"count":25},"Morbid Obesity",4,{"name":27,"count":25},"Oral Lichen Planus",{"name":29,"count":30},"Pancreas Cancer",3,{"name":32,"count":30},"Pneumonia, Viral",{"name":34,"count":30},"Endometrial Cancer",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06935344","Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study","2027-02","Polygenic Risk Score",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,75,93,137,164,190,215,233,259,277,305,331,356,374,402,420,438,465,483,511,529,547,573,599,617,643,669,687,711,729,747,765,790,816,842,876,913,938,962,980,1004,1029,1047,1065,1089,1117,1135,1160,1178,1204,1222,1240,1258,1283,1301,1324,1342,1364,1397,1424,1442,1467,1489,1515,1533,1558,1580,1607,1625,1648,1675,1697,1723,1741,1765,1787,1805,1832,1850,1868,1892,1918,1945,1963,1987,2005,2032],{"intervention":40,"totalTrials":50,"cells":51},1,{"EARLY_PHASE1":52,"PHASE1":55,"PHASE2":57,"PHASE3":59,"PHASE4":61,"NA":63},{"trials":53,"activeCount":54},[],0,{"trials":56,"activeCount":54},[],{"trials":58,"activeCount":54},[],{"trials":60,"activeCount":54},[],{"trials":62,"activeCount":54},[],{"trials":64,"activeCount":50,"soonestReadout":39},[65],{"nctId":37,"briefTitle":38,"status":66,"phases":67,"primaryCompletion":39,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"RECRUITING",[],"2027-05-01","2025-06-01",1300,[72],"Ovarian Cancer",[40,74],"Pharmacogenetic profiles",{"intervention":74,"totalTrials":50,"cells":76},{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":78,"activeCount":54},[],{"trials":80,"activeCount":54},[],{"trials":82,"activeCount":54},[],{"trials":84,"activeCount":54},[],{"trials":86,"activeCount":54},[],{"trials":88,"activeCount":50,"soonestReadout":39},[89],{"nctId":37,"briefTitle":38,"status":66,"phases":90,"primaryCompletion":39,"completion":68,"start":69,"enrollment":70,"conditions":91,"interventions":92},[],[72],[40,74],{"intervention":94,"totalTrials":11,"cells":95},"clopidogrel",{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":119,"NA":135},{"trials":97,"activeCount":54},[],{"trials":99,"activeCount":54},[],{"trials":101,"activeCount":54},[],{"trials":103,"activeCount":54},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"NCT00775762","Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events","UNKNOWN",[45],"2009-01","2010-12","2008-11",213,[114,115],"Polyvascular Disease","Cardiovascular Disease",[117,94,118],"aspirin","clopidogrel plus aspirin",{"trials":120,"activeCount":54},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT02071966","Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS","TERMINATED",[46],"2015-12","2016-11","2012-11",55,[131],"Non ST Segment Elevation Acute Coronary Syndrome",[133,134],"Ticagrelor","Clopidogrel",{"trials":136,"activeCount":54},[],{"intervention":138,"totalTrials":50,"cells":139},"Atazanavir, ritonavir, lamivudine",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":162},{"trials":141,"activeCount":54},[],{"trials":143,"activeCount":54},[],{"trials":145,"activeCount":54},[],{"trials":147,"activeCount":54},[],{"trials":149,"activeCount":54},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":161},"NCT01599364","Atazanavir\u002Fr + Lamivudine Dual Therapy","COMPLETED",[46],"2016-04","2018-02-23","2014-04",266,[160],"Human Immunodeficiency Virus",[138],{"trials":163,"activeCount":54},[],{"intervention":165,"totalTrials":50,"cells":166},"Rifaximin",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":188},{"trials":168,"activeCount":54},[],{"trials":170,"activeCount":54},[],{"trials":172,"activeCount":54},[],{"trials":174,"activeCount":54},[],{"trials":176,"activeCount":54},[177],{"nctId":178,"briefTitle":179,"status":153,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT02068482","Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis",[46],"2012-05","2012-08","2010-11",61,[186],"Diverticular Disease",[165],{"trials":189,"activeCount":54},[],{"intervention":191,"totalTrials":50,"cells":192},"prostacyclin",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":213},{"trials":194,"activeCount":54},[],{"trials":196,"activeCount":54},[],{"trials":198,"activeCount":54},[],{"trials":200,"activeCount":54},[],{"trials":202,"activeCount":54},[203],{"nctId":204,"briefTitle":205,"status":153,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":8,"conditions":209,"interventions":211},"NCT00890214","Prostacyclin's Effect on Platelet Responsiveness",[46],"2008-05","2007-09",[210],"Acute Kidney Failure",[191,212],"heparin",{"trials":214,"activeCount":54},[],{"intervention":212,"totalTrials":50,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":54},[],{"trials":220,"activeCount":54},[],{"trials":222,"activeCount":54},[],{"trials":224,"activeCount":54},[],{"trials":226,"activeCount":54},[227],{"nctId":204,"briefTitle":205,"status":153,"phases":228,"primaryCompletion":207,"completion":207,"start":208,"enrollment":8,"conditions":229,"interventions":230},[46],[210],[191,212],{"trials":232,"activeCount":54},[],{"intervention":234,"totalTrials":50,"cells":235},"Maraviroc, Darunavir\u002Fr",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":257},{"trials":237,"activeCount":54},[],{"trials":239,"activeCount":54},[],{"trials":241,"activeCount":54},[],{"trials":243,"activeCount":54},[],{"trials":245,"activeCount":54},[246],{"nctId":247,"briefTitle":248,"status":124,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":255},"NCT01367210","Switch to Darunavir\u002Fr + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)",[46],"2015-06","2011-06",165,[254],"HIV Infection",[234,256],"current antiretroviral therapy with 3 drugs",{"trials":258,"activeCount":54},[],{"intervention":256,"totalTrials":50,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":262,"activeCount":54},[],{"trials":264,"activeCount":54},[],{"trials":266,"activeCount":54},[],{"trials":268,"activeCount":54},[],{"trials":270,"activeCount":54},[271],{"nctId":247,"briefTitle":248,"status":124,"phases":272,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":273,"interventions":274},[46],[254],[234,256],{"trials":276,"activeCount":54},[],{"intervention":278,"totalTrials":50,"cells":279},"Remifentanil",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":303},{"trials":281,"activeCount":54},[],{"trials":283,"activeCount":54},[],{"trials":285,"activeCount":54},[],{"trials":287,"activeCount":54},[],{"trials":289,"activeCount":54},[290],{"nctId":291,"briefTitle":292,"status":153,"phases":293,"primaryCompletion":294,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":301},"NCT01627873","Effect of Remifentanil on Postoperative Cognition Function in Patients Undergoing Major Abdominal Surgery",[46],"2011-07","2011-12","2009-08",622,[299,300],"Patients Undergoing Major Abdominal Surgery","Postoperative Confusion",[278,302],"Fentanyl",{"trials":304,"activeCount":54},[],{"intervention":306,"totalTrials":50,"cells":307},"ertapenem",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":329},{"trials":309,"activeCount":54},[],{"trials":311,"activeCount":54},[],{"trials":313,"activeCount":54},[],{"trials":315,"activeCount":54},[],{"trials":317,"activeCount":54},[318],{"nctId":319,"briefTitle":320,"status":107,"phases":321,"primaryCompletion":322,"completion":295,"start":323,"enrollment":324,"conditions":325,"interventions":328},"NCT01159379","Safety of Ertapenem in Beta-lactam Allergic Patients.",[46],"2011-09","2011-01",30,[326,327],"IgE-Mediated Hypersensitivity","Allergy",[306],{"trials":330,"activeCount":54},[],{"intervention":332,"totalTrials":50,"cells":333},"Ondansetron",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":342,"NA":354},{"trials":335,"activeCount":54},[],{"trials":337,"activeCount":54},[],{"trials":339,"activeCount":54},[],{"trials":341,"activeCount":54},[],{"trials":343,"activeCount":54},[344],{"nctId":345,"briefTitle":346,"status":153,"phases":347,"primaryCompletion":208,"completion":208,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT00674713","Effect of Acupuncture on Postoperative Nausea and Vomiting",[46],"2006-01",140,[351],"Cholelithiasis",[332,353,332,353],"Physiological saline solution",{"trials":355,"activeCount":54},[],{"intervention":353,"totalTrials":50,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":372},{"trials":359,"activeCount":54},[],{"trials":361,"activeCount":54},[],{"trials":363,"activeCount":54},[],{"trials":365,"activeCount":54},[],{"trials":367,"activeCount":54},[368],{"nctId":345,"briefTitle":346,"status":153,"phases":369,"primaryCompletion":208,"completion":208,"start":348,"enrollment":349,"conditions":370,"interventions":371},[46],[351],[332,353,332,353],{"trials":373,"activeCount":54},[],{"intervention":375,"totalTrials":50,"cells":376},"Lamiduvine",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":400},{"trials":378,"activeCount":54},[],{"trials":380,"activeCount":54},[],{"trials":382,"activeCount":54},[],{"trials":384,"activeCount":54},[],{"trials":386,"activeCount":54},[387],{"nctId":388,"briefTitle":389,"status":153,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT00885482","Atazanavir and Lamivudine for Treatment Simplification",[46],"2010-05","2011-05","2009-05",40,[396],"HIV Infections",[375,398,399],"Atazanavir","Ritonavir",{"trials":401,"activeCount":54},[],{"intervention":398,"totalTrials":50,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":418},{"trials":405,"activeCount":54},[],{"trials":407,"activeCount":54},[],{"trials":409,"activeCount":54},[],{"trials":411,"activeCount":54},[],{"trials":413,"activeCount":54},[414],{"nctId":388,"briefTitle":389,"status":153,"phases":415,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":416,"interventions":417},[46],[396],[375,398,399],{"trials":419,"activeCount":54},[],{"intervention":399,"totalTrials":50,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":436},{"trials":423,"activeCount":54},[],{"trials":425,"activeCount":54},[],{"trials":427,"activeCount":54},[],{"trials":429,"activeCount":54},[],{"trials":431,"activeCount":54},[432],{"nctId":388,"briefTitle":389,"status":153,"phases":433,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":434,"interventions":435},[46],[396],[375,398,399],{"trials":437,"activeCount":54},[],{"intervention":439,"totalTrials":50,"cells":440},"Sodium Oxybate",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":463},{"trials":442,"activeCount":54},[],{"trials":444,"activeCount":54},[],{"trials":446,"activeCount":54},[],{"trials":448,"activeCount":54},[],{"trials":450,"activeCount":54},[451],{"nctId":452,"briefTitle":453,"status":153,"phases":454,"primaryCompletion":455,"completion":393,"start":456,"enrollment":457,"conditions":458,"interventions":461},"NCT02090504","Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome",[46],"2009-04","2002-02",127,[459,460],"Alcohol Withdrawal Syndrome","Alcohol Dependence",[439,462],"Oxazepam",{"trials":464,"activeCount":54},[],{"intervention":462,"totalTrials":50,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":54},[],{"trials":470,"activeCount":54},[],{"trials":472,"activeCount":54},[],{"trials":474,"activeCount":54},[],{"trials":476,"activeCount":54},[477],{"nctId":452,"briefTitle":453,"status":153,"phases":478,"primaryCompletion":455,"completion":393,"start":456,"enrollment":457,"conditions":479,"interventions":480},[46],[459,460],[439,462],{"trials":482,"activeCount":54},[],{"intervention":484,"totalTrials":50,"cells":485},"TELMISARTAN",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":509},{"trials":487,"activeCount":54},[],{"trials":489,"activeCount":54},[],{"trials":491,"activeCount":54},[],{"trials":493,"activeCount":54},[],{"trials":495,"activeCount":54},[496],{"nctId":497,"briefTitle":498,"status":107,"phases":499,"primaryCompletion":500,"completion":111,"start":501,"enrollment":502,"conditions":503,"interventions":507},"NCT00702936","Telmisartan Versus Ramipril After Acute Coronary Syndrome",[46],"2008-08","2007-11",50,[504,505,506],"Acute Coronary Syndrome","Myocardial Infarction","Coronary Disease",[484,508],"RAMIPRIL",{"trials":510,"activeCount":54},[],{"intervention":508,"totalTrials":50,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":527},{"trials":514,"activeCount":54},[],{"trials":516,"activeCount":54},[],{"trials":518,"activeCount":54},[],{"trials":520,"activeCount":54},[],{"trials":522,"activeCount":54},[523],{"nctId":497,"briefTitle":498,"status":107,"phases":524,"primaryCompletion":500,"completion":111,"start":501,"enrollment":502,"conditions":525,"interventions":526},[46],[504,505,506],[484,508],{"trials":528,"activeCount":54},[],{"intervention":133,"totalTrials":50,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":54},[],{"trials":534,"activeCount":54},[],{"trials":536,"activeCount":54},[],{"trials":538,"activeCount":54},[],{"trials":540,"activeCount":54},[541],{"nctId":122,"briefTitle":123,"status":124,"phases":542,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":543,"interventions":544},[46],[131],[133,134],{"trials":546,"activeCount":54},[],{"intervention":548,"totalTrials":50,"cells":549},"Neoadjuvant chemotherapy + Interval Debulking Surgery",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":569,"NA":571},{"trials":551,"activeCount":54},[],{"trials":553,"activeCount":54},[],{"trials":555,"activeCount":54},[],{"trials":557,"activeCount":54},[558],{"nctId":559,"briefTitle":560,"status":153,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT01461850","Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm",[45],"2014-11-30","2016-05-31","2011-10-01",171,[567],"Stage IIIC Ovarian Cancer",[548],{"trials":570,"activeCount":54},[],{"trials":572,"activeCount":54},[],{"intervention":574,"totalTrials":50,"cells":575},"XELAC RT",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":595,"NA":597},{"trials":577,"activeCount":54},[],{"trials":579,"activeCount":54},[],{"trials":581,"activeCount":54},[],{"trials":583,"activeCount":54},[584],{"nctId":585,"briefTitle":586,"status":107,"phases":587,"primaryCompletion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT01653301","Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study",[45],"2012-12","2005-10",616,[592],"Rectal Cancer",[574,594],"XELOX RT",{"trials":596,"activeCount":54},[],{"trials":598,"activeCount":54},[],{"intervention":594,"totalTrials":50,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":54},[],{"trials":604,"activeCount":54},[],{"trials":606,"activeCount":54},[],{"trials":608,"activeCount":54},[609],{"nctId":585,"briefTitle":586,"status":107,"phases":610,"primaryCompletion":588,"start":589,"enrollment":590,"conditions":611,"interventions":612},[45],[592],[574,594],{"trials":614,"activeCount":54},[],{"trials":616,"activeCount":54},[],{"intervention":618,"totalTrials":50,"cells":619},"Lactobacillus brevis CD2",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":639,"NA":641},{"trials":621,"activeCount":54},[],{"trials":623,"activeCount":54},[],{"trials":625,"activeCount":54},[],{"trials":627,"activeCount":54},[628],{"nctId":629,"briefTitle":630,"status":107,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT02085694","Lactobacillus Brevis CD2 Preventing Oral Mucositis",[44,45],"2014-11","2014-12","2014-03",10,[637],"Mucositis",[618],{"trials":640,"activeCount":54},[],{"trials":642,"activeCount":54},[],{"intervention":644,"totalTrials":50,"cells":645},"Yasmin;",{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":652,"PHASE4":665,"NA":667},{"trials":647,"activeCount":54},[],{"trials":649,"activeCount":54},[],{"trials":651,"activeCount":54},[],{"trials":653,"activeCount":54},[654],{"nctId":655,"briefTitle":656,"status":153,"phases":657,"primaryCompletion":294,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT01581814","Effects of Drospirenone-ethinylestradiol and\u002For Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome",[45],"2012-03","2008-10",99,[15],[663,644,664],"Metformin","Metformin plus Yasmin",{"trials":666,"activeCount":54},[],{"trials":668,"activeCount":54},[],{"intervention":664,"totalTrials":50,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":54},[],{"trials":674,"activeCount":54},[],{"trials":676,"activeCount":54},[],{"trials":678,"activeCount":54},[679],{"nctId":655,"briefTitle":656,"status":153,"phases":680,"primaryCompletion":294,"completion":658,"start":659,"enrollment":660,"conditions":681,"interventions":682},[45],[15],[663,644,664],{"trials":684,"activeCount":54},[],{"trials":686,"activeCount":54},[],{"intervention":688,"totalTrials":50,"cells":689},"adenosine",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":707,"NA":709},{"trials":691,"activeCount":54},[],{"trials":693,"activeCount":54},[],{"trials":695,"activeCount":54},[],{"trials":697,"activeCount":54},[698],{"nctId":699,"briefTitle":700,"status":153,"phases":701,"primaryCompletion":251,"completion":322,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT00590070","THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction",[44,45],"2008-01",240,[505],[688,706],"nitroprusside",{"trials":708,"activeCount":54},[],{"trials":710,"activeCount":54},[],{"intervention":706,"totalTrials":50,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":725,"NA":727},{"trials":714,"activeCount":54},[],{"trials":716,"activeCount":54},[],{"trials":718,"activeCount":54},[],{"trials":720,"activeCount":54},[721],{"nctId":699,"briefTitle":700,"status":153,"phases":722,"primaryCompletion":251,"completion":322,"start":702,"enrollment":703,"conditions":723,"interventions":724},[44,45],[505],[688,706],{"trials":726,"activeCount":54},[],{"trials":728,"activeCount":54},[],{"intervention":117,"totalTrials":50,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":743,"NA":745},{"trials":732,"activeCount":54},[],{"trials":734,"activeCount":54},[],{"trials":736,"activeCount":54},[],{"trials":738,"activeCount":54},[739],{"nctId":105,"briefTitle":106,"status":107,"phases":740,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":741,"interventions":742},[45],[114,115],[117,94,118],{"trials":744,"activeCount":54},[],{"trials":746,"activeCount":54},[],{"intervention":118,"totalTrials":50,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":761,"NA":763},{"trials":750,"activeCount":54},[],{"trials":752,"activeCount":54},[],{"trials":754,"activeCount":54},[],{"trials":756,"activeCount":54},[757],{"nctId":105,"briefTitle":106,"status":107,"phases":758,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":759,"interventions":760},[45],[114,115],[117,94,118],{"trials":762,"activeCount":54},[],{"trials":764,"activeCount":54},[],{"intervention":766,"totalTrials":50,"cells":767},"montelukast sodium",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":774,"PHASE4":786,"NA":788},{"trials":769,"activeCount":54},[],{"trials":771,"activeCount":54},[],{"trials":773,"activeCount":54},[],{"trials":775,"activeCount":54},[776],{"nctId":777,"briefTitle":778,"status":153,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT00675285","Effects of Montelukast in Children With Asthma",[45],"2006-07","2005-09",26,[784],"Asthma",[766],{"trials":787,"activeCount":54},[],{"trials":789,"activeCount":54},[],{"intervention":791,"totalTrials":50,"cells":792},"BOTOX",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":812,"NA":814},{"trials":794,"activeCount":54},[],{"trials":796,"activeCount":54},[],{"trials":798,"activeCount":54},[],{"trials":800,"activeCount":54},[801],{"nctId":802,"briefTitle":803,"status":153,"phases":804,"primaryCompletion":805,"start":806,"enrollment":807,"conditions":808,"interventions":811},"NCT01566292","Intraprostatic Botulinum Toxin Type \"A\" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy",[44,45],"2010-09","2009-09",33,[809,810],"Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Enlargement (BPE)",[791],{"trials":813,"activeCount":54},[],{"trials":815,"activeCount":54},[],{"intervention":817,"totalTrials":50,"cells":818},"Methylprednisolone",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":838,"NA":840},{"trials":820,"activeCount":54},[],{"trials":822,"activeCount":54},[],{"trials":824,"activeCount":54},[],{"trials":826,"activeCount":54},[827],{"nctId":828,"briefTitle":829,"status":107,"phases":830,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":837},"NCT00562835","Steroids in Patients With Early ARDS",[44,45],"2009-02","2008-02",400,[835,836],"Acute Lung Injury","ARDS, Human",[817],{"trials":839,"activeCount":54},[],{"trials":841,"activeCount":54},[],{"intervention":843,"totalTrials":11,"cells":844},"Indocyanine Green",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":846,"activeCount":54},[],{"trials":848,"activeCount":54},[],{"trials":850,"activeCount":54},[851,862],{"nctId":852,"briefTitle":853,"status":153,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":861},"NCT03332004","Near-infrared Fluorescence Imaging as a Supportive Tool for Localisation of Deep Infiltrating Endometriosis During Laparoscopy",[44],"2017-02-16","2016-01-04",27,[859,860],"Pelvic Endometriosis","Endometriosis Outside Pelvis",[843],{"nctId":863,"briefTitle":864,"status":153,"phases":865,"primaryCompletion":866,"completion":866,"start":856,"enrollment":867,"conditions":868,"interventions":869},"NCT03935165","Prospective Evaluation of Near-infrared Fluorescence Imaging Use as a Supportive Tool in Deep Infiltrating Endometriosis Surgery",[44],"2019-05-19",51,[859,860],[843],{"trials":871,"activeCount":54},[],{"trials":873,"activeCount":54},[],{"trials":875,"activeCount":54},[],{"intervention":877,"totalTrials":11,"cells":878},"Vancomycin",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":880,"activeCount":54},[],{"trials":882,"activeCount":54},[],{"trials":884,"activeCount":54},[885,895],{"nctId":886,"briefTitle":887,"status":153,"phases":888,"primaryCompletion":632,"completion":632,"start":889,"enrollment":890,"conditions":891,"interventions":893},"NCT02148601","Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection",[44],"2013-07",39,[892],"Clostridium Difficile",[894,877],"Standard Antibiotic Therapy",{"nctId":896,"briefTitle":897,"status":153,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT03427229","Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection",[44],"2017-10-30","2016-03",58,[892,903],"Pseudomembranous Colitis",[905,877,906],"Single-infusion FMT","multiple-infusion FMT",{"trials":908,"activeCount":54},[],{"trials":910,"activeCount":54},[],{"trials":912,"activeCount":54},[],{"intervention":914,"totalTrials":50,"cells":915},"Epigallocatechin-gallate",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":917,"activeCount":54},[],{"trials":919,"activeCount":54},[],{"trials":921,"activeCount":54},[922],{"nctId":923,"briefTitle":924,"status":107,"phases":925,"completion":926,"start":927,"enrollment":394,"conditions":928,"interventions":931},"NCT00476138","Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma",[43,44],"2008-07","2006-11",[929,930],"Primary Open Angle Glaucoma","Ocular Hypertension",[914],{"trials":933,"activeCount":54},[],{"trials":935,"activeCount":54},[],{"trials":937,"activeCount":54},[],{"intervention":939,"totalTrials":50,"cells":940},"Group A: NCA 600 mg+antibiotics",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":942,"activeCount":54},[],{"trials":944,"activeCount":54},[],{"trials":946,"activeCount":54},[947],{"nctId":948,"briefTitle":949,"status":107,"phases":950,"primaryCompletion":951,"completion":806,"start":455,"enrollment":394,"conditions":952,"interventions":954},"NCT00985608","Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study",[44],"2009-07",[953],"Helicobacter Pylori Infection",[939,955],"Group B: antibiotic treatment",{"trials":957,"activeCount":54},[],{"trials":959,"activeCount":54},[],{"trials":961,"activeCount":54},[],{"intervention":955,"totalTrials":50,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":965,"activeCount":54},[],{"trials":967,"activeCount":54},[],{"trials":969,"activeCount":54},[970],{"nctId":948,"briefTitle":949,"status":107,"phases":971,"primaryCompletion":951,"completion":806,"start":455,"enrollment":394,"conditions":972,"interventions":973},[44],[953],[939,955],{"trials":975,"activeCount":54},[],{"trials":977,"activeCount":54},[],{"trials":979,"activeCount":54},[],{"intervention":981,"totalTrials":50,"cells":982},"Trabectedin",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":984,"activeCount":54},[],{"trials":986,"activeCount":54},[],{"trials":988,"activeCount":54},[989],{"nctId":990,"briefTitle":991,"status":107,"phases":992,"primaryCompletion":993,"completion":993,"start":251,"enrollment":994,"conditions":995,"interventions":997},"NCT01772979","Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer",[44],"2014-06",100,[996],"BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype",[981],{"trials":999,"activeCount":54},[],{"trials":1001,"activeCount":54},[],{"trials":1003,"activeCount":54},[],{"intervention":1005,"totalTrials":50,"cells":1006},"tenofovir emtricitabine raltegravir",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1008,"activeCount":54},[],{"trials":1010,"activeCount":54},[],{"trials":1012,"activeCount":54},[1013],{"nctId":1014,"briefTitle":1015,"status":153,"phases":1016,"primaryCompletion":183,"completion":110,"start":296,"enrollment":394,"conditions":1017,"interventions":1020},"NCT00958100","Raltegravir Switch for Toxicity or Adverse Events",[44],[1018,1019,396],"HIV\u002FAIDS","Antiretroviral Therapy",[1005,1021,1022],"Lamivudine Abacavir Raltegravir","Abacavir free",{"trials":1024,"activeCount":54},[],{"trials":1026,"activeCount":54},[],{"trials":1028,"activeCount":54},[],{"intervention":1021,"totalTrials":50,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1032,"activeCount":54},[],{"trials":1034,"activeCount":54},[],{"trials":1036,"activeCount":54},[1037],{"nctId":1014,"briefTitle":1015,"status":153,"phases":1038,"primaryCompletion":183,"completion":110,"start":296,"enrollment":394,"conditions":1039,"interventions":1040},[44],[1018,1019,396],[1005,1021,1022],{"trials":1042,"activeCount":54},[],{"trials":1044,"activeCount":54},[],{"trials":1046,"activeCount":54},[],{"intervention":1022,"totalTrials":50,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1050,"activeCount":54},[],{"trials":1052,"activeCount":54},[],{"trials":1054,"activeCount":54},[1055],{"nctId":1014,"briefTitle":1015,"status":153,"phases":1056,"primaryCompletion":183,"completion":110,"start":296,"enrollment":394,"conditions":1057,"interventions":1058},[44],[1018,1019,396],[1005,1021,1022],{"trials":1060,"activeCount":54},[],{"trials":1062,"activeCount":54},[],{"trials":1064,"activeCount":54},[],{"intervention":1066,"totalTrials":50,"cells":1067},"Baclofen",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1069,"activeCount":54},[],{"trials":1071,"activeCount":54},[],{"trials":1073,"activeCount":54},[1074],{"nctId":1075,"briefTitle":1076,"status":153,"phases":1077,"completion":927,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1082},"NCT00525252","Efficacy of Baclofen in the Treatment of Alcohol Addiction",[43,44],"2003-02",86,[1081],"Liver Cirrhosis, Alcoholic",[1066],{"trials":1084,"activeCount":54},[],{"trials":1086,"activeCount":54},[],{"trials":1088,"activeCount":54},[],{"intervention":1090,"totalTrials":50,"cells":1091},"rhu G-CSF",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1093,"activeCount":54},[],{"trials":1095,"activeCount":54},[],{"trials":1097,"activeCount":54},[1098],{"nctId":1099,"briefTitle":1100,"status":1101,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":54,"conditions":1106,"interventions":1109},"NCT02502747","RIGENERA 2.0 Trial","WITHDRAWN",[44],"2021-10","2021-12","2020-01",[1107,1108],"Anterior Myocardial Infarction","Heart Failure",[1090,1110],"optimal standard of care",{"trials":1112,"activeCount":54},[],{"trials":1114,"activeCount":54},[],{"trials":1116,"activeCount":54},[],{"intervention":1110,"totalTrials":50,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1120,"activeCount":54},[],{"trials":1122,"activeCount":54},[],{"trials":1124,"activeCount":54},[1125],{"nctId":1099,"briefTitle":1100,"status":1101,"phases":1126,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":54,"conditions":1127,"interventions":1128},[44],[1107,1108],[1090,1110],{"trials":1130,"activeCount":54},[],{"trials":1132,"activeCount":54},[],{"trials":1134,"activeCount":54},[],{"intervention":1136,"totalTrials":50,"cells":1137},"Carboplatin plus Celecoxib",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1139,"activeCount":54},[],{"trials":1141,"activeCount":54},[],{"trials":1143,"activeCount":54},[1144],{"nctId":1145,"briefTitle":1146,"status":153,"phases":1147,"primaryCompletion":208,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT01124435","Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients",[44],"2008-12","2003-10",45,[1152],"Ovarian Neoplasms",[1136],{"trials":1155,"activeCount":54},[],{"trials":1157,"activeCount":54},[],{"trials":1159,"activeCount":54},[],{"intervention":894,"totalTrials":50,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1163,"activeCount":54},[],{"trials":1165,"activeCount":54},[],{"trials":1167,"activeCount":54},[1168],{"nctId":886,"briefTitle":887,"status":153,"phases":1169,"primaryCompletion":632,"completion":632,"start":889,"enrollment":890,"conditions":1170,"interventions":1171},[44],[892],[894,877],{"trials":1173,"activeCount":54},[],{"trials":1175,"activeCount":54},[],{"trials":1177,"activeCount":54},[],{"intervention":1179,"totalTrials":50,"cells":1180},"Bevacizumab",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1182,"activeCount":54},[],{"trials":1184,"activeCount":54},[],{"trials":1186,"activeCount":54},[1187],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1196},"NCT01770171","Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer",[44],"2017-12","2012-04",108,[1195],"Stage III-IV or Recurrent Endometrial Cancer",[1179,1197],"Carboplatin AUC 5+Paclitaxel 175 mg\u002Fmq q 21 for 6-8 cycles",{"trials":1199,"activeCount":54},[],{"trials":1201,"activeCount":54},[],{"trials":1203,"activeCount":54},[],{"intervention":1197,"totalTrials":50,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":54},[],{"trials":1209,"activeCount":54},[],{"trials":1211,"activeCount":54},[1212],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1213,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1214,"interventions":1215},[44],[1195],[1179,1197],{"trials":1217,"activeCount":54},[],{"trials":1219,"activeCount":54},[],{"trials":1221,"activeCount":54},[],{"intervention":905,"totalTrials":50,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":54},[],{"trials":1227,"activeCount":54},[],{"trials":1229,"activeCount":54},[1230],{"nctId":896,"briefTitle":897,"status":153,"phases":1231,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":1232,"interventions":1233},[44],[892,903],[905,877,906],{"trials":1235,"activeCount":54},[],{"trials":1237,"activeCount":54},[],{"trials":1239,"activeCount":54},[],{"intervention":906,"totalTrials":50,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":54},[],{"trials":1245,"activeCount":54},[],{"trials":1247,"activeCount":54},[1248],{"nctId":896,"briefTitle":897,"status":153,"phases":1249,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":1250,"interventions":1251},[44],[892,903],[905,877,906],{"trials":1253,"activeCount":54},[],{"trials":1255,"activeCount":54},[],{"trials":1257,"activeCount":54},[],{"intervention":1259,"totalTrials":50,"cells":1260},"Meropur 150 a day",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1262,"activeCount":54},[],{"trials":1264,"activeCount":54},[1265],{"nctId":1266,"briefTitle":1267,"status":153,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":181,"enrollment":1270,"conditions":1271,"interventions":1273},"NCT01604044","Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.",[43],"2013-09",579,[1272],"Female Infertility",[1259,1274],"Gonal-f 150 plus Luveris 150",{"trials":1276,"activeCount":54},[],{"trials":1278,"activeCount":54},[],{"trials":1280,"activeCount":54},[],{"trials":1282,"activeCount":54},[],{"intervention":1274,"totalTrials":50,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1293,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1286,"activeCount":54},[],{"trials":1288,"activeCount":54},[1289],{"nctId":1266,"briefTitle":1267,"status":153,"phases":1290,"primaryCompletion":1269,"completion":1269,"start":181,"enrollment":1270,"conditions":1291,"interventions":1292},[43],[1272],[1259,1274],{"trials":1294,"activeCount":54},[],{"trials":1296,"activeCount":54},[],{"trials":1298,"activeCount":54},[],{"trials":1300,"activeCount":54},[],{"intervention":1302,"totalTrials":50,"cells":1303},"Zoely",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1305,"activeCount":54},[],{"trials":1307,"activeCount":54},[1308],{"nctId":1309,"briefTitle":1310,"status":107,"phases":1311,"primaryCompletion":181,"completion":1312,"start":1192,"enrollment":635,"conditions":1313,"interventions":1314},"NCT01603745","Effects of Drospirenone-ethinylestradiol and\u002For NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome",[43],"2012-10",[15],[1302,1315],"Yasmin",{"trials":1317,"activeCount":54},[],{"trials":1319,"activeCount":54},[],{"trials":1321,"activeCount":54},[],{"trials":1323,"activeCount":54},[],{"intervention":1315,"totalTrials":50,"cells":1325},{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1340},{"trials":1327,"activeCount":54},[],{"trials":1329,"activeCount":54},[1330],{"nctId":1309,"briefTitle":1310,"status":107,"phases":1331,"primaryCompletion":181,"completion":1312,"start":1192,"enrollment":635,"conditions":1332,"interventions":1333},[43],[15],[1302,1315],{"trials":1335,"activeCount":54},[],{"trials":1337,"activeCount":54},[],{"trials":1339,"activeCount":54},[],{"trials":1341,"activeCount":54},[],{"intervention":1343,"totalTrials":50,"cells":1344},"Inositol",{"EARLY_PHASE1":1345,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1346,"activeCount":54},[1347],{"nctId":1348,"briefTitle":1349,"status":107,"phases":1350,"primaryCompletion":182,"start":658,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT01574261","Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial",[42],70,[15],[1343],{"trials":1355,"activeCount":54},[],{"trials":1357,"activeCount":54},[],{"trials":1359,"activeCount":54},[],{"trials":1361,"activeCount":54},[],{"trials":1363,"activeCount":54},[],{"intervention":663,"totalTrials":30,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1378,"NA":1380},{"trials":1367,"activeCount":54},[],{"trials":1369,"activeCount":54},[],{"trials":1371,"activeCount":54},[],{"trials":1373,"activeCount":54},[1374],{"nctId":655,"briefTitle":656,"status":153,"phases":1375,"primaryCompletion":294,"completion":658,"start":659,"enrollment":660,"conditions":1376,"interventions":1377},[45],[15],[663,644,664],{"trials":1379,"activeCount":54},[],{"trials":1381,"activeCount":54},[1382,1390],{"nctId":1383,"briefTitle":1384,"status":107,"phases":1385,"primaryCompletion":1191,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT02984722","Extended-release vs Immediate-release Metformin in PCOS Women",[47],"2016-12",80,[15],[663],{"nctId":1391,"briefTitle":1392,"status":153,"phases":1393,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT01594697","Metformin in Pregnancy in Women With Polycystic Ovary Syndrome",[47],60,[15],[663],{"intervention":302,"totalTrials":11,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1413},{"trials":1400,"activeCount":54},[],{"trials":1402,"activeCount":54},[],{"trials":1404,"activeCount":54},[],{"trials":1406,"activeCount":54},[],{"trials":1408,"activeCount":54},[1409],{"nctId":291,"briefTitle":292,"status":153,"phases":1410,"primaryCompletion":294,"completion":295,"start":296,"enrollment":297,"conditions":1411,"interventions":1412},[46],[299,300],[278,302],{"trials":1414,"activeCount":54},[1415],{"nctId":1416,"briefTitle":1417,"status":153,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1192,"enrollment":1394,"conditions":1420,"interventions":1422},"NCT02146638","Post Operative Pain Control: Morphine vs Fentanyl",[47],"2012-09",[1421],"Post Operative Analgesia",[1423,302],"Morphine",{"intervention":1423,"totalTrials":50,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":54},[],{"trials":1429,"activeCount":54},[],{"trials":1431,"activeCount":54},[],{"trials":1433,"activeCount":54},[],{"trials":1435,"activeCount":54},[],{"trials":1437,"activeCount":54},[1438],{"nctId":1416,"briefTitle":1417,"status":153,"phases":1439,"primaryCompletion":1419,"completion":1419,"start":1192,"enrollment":1394,"conditions":1440,"interventions":1441},[47],[1421],[1423,302],{"intervention":1443,"totalTrials":50,"cells":1444},"1 mg of transdermal estradiol daily and 10mg of oral MPA",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1446,"activeCount":54},[],{"trials":1448,"activeCount":54},[],{"trials":1450,"activeCount":54},[],{"trials":1452,"activeCount":54},[],{"trials":1454,"activeCount":54},[],{"trials":1456,"activeCount":54},[1457],{"nctId":1458,"briefTitle":1459,"status":107,"phases":1460,"primaryCompletion":1461,"completion":1191,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1466},"NCT02984696","Total Antioxidant Capacity Before and After HRT in Hypotalamic Amenorrhea",[47],"2016-10","2015-03",20,[1465],"Hypothalamic Amenorrhea",[1443],{"intervention":1468,"totalTrials":50,"cells":1469},"Melatonin",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1471,"activeCount":54},[],{"trials":1473,"activeCount":54},[],{"trials":1475,"activeCount":54},[],{"trials":1477,"activeCount":54},[],{"trials":1479,"activeCount":54},[],{"trials":1481,"activeCount":54},[1482],{"nctId":1483,"briefTitle":1484,"status":107,"phases":1485,"primaryCompletion":1486,"start":250,"enrollment":394,"conditions":1487,"interventions":1488},"NCT02663570","Effects of Melatonin in PCOS Women",[47],"2016-01",[15],[1468],{"intervention":1490,"totalTrials":50,"cells":1491},"myo-inositol 1500 gr",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":54},[],{"trials":1495,"activeCount":54},[],{"trials":1497,"activeCount":54},[],{"trials":1499,"activeCount":54},[],{"trials":1501,"activeCount":54},[],{"trials":1503,"activeCount":54},[1504],{"nctId":1505,"briefTitle":1506,"status":153,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":502,"conditions":1510,"interventions":1513},"NCT01555190","Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone",[47],"2013-12","2012-01",[15,1511,1512],"Hirsutism","Menstrual Irregularity",[1490,1514],"myo-inositol 2000 gr + folic acid 200 mcg",{"intervention":1514,"totalTrials":50,"cells":1516},{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1518,"activeCount":54},[],{"trials":1520,"activeCount":54},[],{"trials":1522,"activeCount":54},[],{"trials":1524,"activeCount":54},[],{"trials":1526,"activeCount":54},[],{"trials":1528,"activeCount":54},[1529],{"nctId":1505,"briefTitle":1506,"status":153,"phases":1530,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":502,"conditions":1531,"interventions":1532},[47],[15,1511,1512],[1490,1514],{"intervention":1534,"totalTrials":50,"cells":1535},"LIRAGLUTIDE 3 Mg\u002F0.5 mL",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1537,"activeCount":54},[],{"trials":1539,"activeCount":54},[],{"trials":1541,"activeCount":54},[],{"trials":1543,"activeCount":54},[],{"trials":1545,"activeCount":54},[],{"trials":1547,"activeCount":54},[1548],{"nctId":1549,"briefTitle":1550,"status":153,"phases":1551,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1557},"NCT03534310","Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg",[47],"2017-01-31","2017-04-10","2015-11-02",75,[18],[1534],{"intervention":1559,"totalTrials":50,"cells":1560},"Alpha-lipoic acid",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1562,"activeCount":54},[],{"trials":1564,"activeCount":54},[],{"trials":1566,"activeCount":54},[],{"trials":1568,"activeCount":54},[],{"trials":1570,"activeCount":54},[],{"trials":1572,"activeCount":54},[1573],{"nctId":1574,"briefTitle":1575,"status":107,"phases":1576,"primaryCompletion":1577,"start":1486,"enrollment":394,"conditions":1578,"interventions":1579},"NCT02666170","Effects of Alpha-acid Lipoic in PCOS Women",[47],"2016-09",[15],[1559],{"intervention":1581,"totalTrials":50,"cells":1582},"polyethylene glycol",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1584,"activeCount":54},[],{"trials":1586,"activeCount":54},[],{"trials":1588,"activeCount":54},[],{"trials":1590,"activeCount":54},[],{"trials":1592,"activeCount":54},[],{"trials":1594,"activeCount":54},[1595],{"nctId":1596,"briefTitle":1597,"status":153,"phases":1598,"primaryCompletion":183,"completion":183,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1605},"NCT01533090","Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy",[47],"2010-04",162,[1602,1603,1604],"Colonic Polyps","Cancer Colon","Inflammatory Bowel Disease",[1581,1606],"PEG low volume with bisacodyl",{"intervention":1606,"totalTrials":50,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1610,"activeCount":54},[],{"trials":1612,"activeCount":54},[],{"trials":1614,"activeCount":54},[],{"trials":1616,"activeCount":54},[],{"trials":1618,"activeCount":54},[],{"trials":1620,"activeCount":54},[1621],{"nctId":1596,"briefTitle":1597,"status":153,"phases":1622,"primaryCompletion":183,"completion":183,"start":1599,"enrollment":1600,"conditions":1623,"interventions":1624},[47],[1602,1603,1604],[1581,1606],{"intervention":1626,"totalTrials":50,"cells":1627},"Remifentanil Injectable Product",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1638},{"trials":1629,"activeCount":54},[],{"trials":1631,"activeCount":54},[],{"trials":1633,"activeCount":54},[],{"trials":1635,"activeCount":54},[],{"trials":1637,"activeCount":54},[],{"trials":1639,"activeCount":54},[1640],{"nctId":1641,"briefTitle":1642,"status":153,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":702,"enrollment":502,"conditions":1645,"interventions":1647},"NCT03378674","Remifentanil and Stress Hormones Response",[47],"2012-07",[1646],"Stress Response",[1626],{"intervention":1649,"totalTrials":50,"cells":1650},"Poractant alfa, 200 mg\u002Fkg",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1652,"activeCount":54},[],{"trials":1654,"activeCount":54},[],{"trials":1656,"activeCount":54},[],{"trials":1658,"activeCount":54},[],{"trials":1660,"activeCount":54},[],{"trials":1662,"activeCount":54},[1663],{"nctId":1664,"briefTitle":1665,"status":153,"phases":1666,"primaryCompletion":1667,"completion":1668,"start":1669,"enrollment":1670,"conditions":1671,"interventions":1674},"NCT02482766","Efficacy of a New Technique -\"IN-REC-SUR-E\"- in Preterm Neonates With RDS",[47],"2018-09","2018-09-30","2015-11",206,[1672,1673],"Respiratory Distress Syndrome","Hyaline Membrane Disease",[1649],{"intervention":1676,"totalTrials":50,"cells":1677},"Dopamine",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1679,"activeCount":54},[],{"trials":1681,"activeCount":54},[],{"trials":1683,"activeCount":54},[],{"trials":1685,"activeCount":54},[],{"trials":1687,"activeCount":54},[],{"trials":1689,"activeCount":54},[1690],{"nctId":1691,"briefTitle":1692,"status":153,"phases":1693,"primaryCompletion":1644,"completion":1312,"start":658,"enrollment":1394,"conditions":1694,"interventions":1696},"NCT01722630","Renal Function During Laparoscopic Surgery",[47],[1695],"Intra Operative Fluid Management",[1676],{"intervention":1698,"totalTrials":50,"cells":1699},"Intravenous anesthetic",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1701,"activeCount":54},[],{"trials":1703,"activeCount":54},[],{"trials":1705,"activeCount":54},[],{"trials":1707,"activeCount":54},[],{"trials":1709,"activeCount":54},[],{"trials":1711,"activeCount":54},[1712],{"nctId":1713,"briefTitle":1714,"status":153,"phases":1715,"primaryCompletion":1716,"completion":1716,"start":1717,"enrollment":1394,"conditions":1718,"interventions":1721},"NCT03157479","Intraoperative Protective Ventilation for Obese Patients Undergoing Gynaecological Laparoscopic Surgery",[47],"2019-03-31","2017-05-01",[1719,1720],"Anesthesia","Surgery--Complications",[1698,1722],"Crystalloid Solutions",{"intervention":1722,"totalTrials":50,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1726,"activeCount":54},[],{"trials":1728,"activeCount":54},[],{"trials":1730,"activeCount":54},[],{"trials":1732,"activeCount":54},[],{"trials":1734,"activeCount":54},[],{"trials":1736,"activeCount":54},[1737],{"nctId":1713,"briefTitle":1714,"status":153,"phases":1738,"primaryCompletion":1716,"completion":1716,"start":1717,"enrollment":1394,"conditions":1739,"interventions":1740},[47],[1719,1720],[1698,1722],{"intervention":1742,"totalTrials":50,"cells":1743},"Rapid fluid load test",{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1745,"activeCount":54},[],{"trials":1747,"activeCount":54},[],{"trials":1749,"activeCount":54},[],{"trials":1751,"activeCount":54},[],{"trials":1753,"activeCount":54},[],{"trials":1755,"activeCount":54},[1756],{"nctId":1757,"briefTitle":1758,"status":107,"phases":1759,"primaryCompletion":993,"completion":993,"start":1760,"enrollment":1761,"conditions":1762,"interventions":1764},"NCT01840670","Central Venous and Abdominal Pressures and the Inferior Vena Cava",[],"2013-05",16,[1763],"Hypovolemia",[1742],{"intervention":1766,"totalTrials":50,"cells":1767},"metformin 1500 mg",{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1774,"PHASE4":1776,"NA":1778},{"trials":1769,"activeCount":54},[],{"trials":1771,"activeCount":54},[],{"trials":1773,"activeCount":54},[],{"trials":1775,"activeCount":54},[],{"trials":1777,"activeCount":54},[],{"trials":1779,"activeCount":54},[1780],{"nctId":1781,"briefTitle":1782,"status":153,"phases":1783,"primaryCompletion":588,"completion":588,"start":251,"enrollment":394,"conditions":1784,"interventions":1785},"NCT01791647","Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome",[47],[15],[1766,1786],"myoinositol 1500 mg",{"intervention":1786,"totalTrials":50,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1790,"activeCount":54},[],{"trials":1792,"activeCount":54},[],{"trials":1794,"activeCount":54},[],{"trials":1796,"activeCount":54},[],{"trials":1798,"activeCount":54},[],{"trials":1800,"activeCount":54},[1801],{"nctId":1781,"briefTitle":1782,"status":153,"phases":1802,"primaryCompletion":588,"completion":588,"start":251,"enrollment":394,"conditions":1803,"interventions":1804},[47],[15],[1766,1786],{"intervention":1806,"totalTrials":50,"cells":1807},"Fluid resuscitation or amine administration",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1809,"activeCount":54},[],{"trials":1811,"activeCount":54},[],{"trials":1813,"activeCount":54},[],{"trials":1815,"activeCount":54},[],{"trials":1817,"activeCount":54},[],{"trials":1819,"activeCount":54},[1820],{"nctId":1821,"briefTitle":1822,"status":153,"phases":1823,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":324,"conditions":1826,"interventions":1829},"NCT03083457","Physiological Effects of Lung Recruitment During General Anesthesia and Low-tidal Volume Ventilation",[47],"2020-11-30","2017-03-20",[1827,1828],"Anesthesia, General","Surgery",[1806,1830,1831],"General anesthetic","Fluid administration",{"intervention":1830,"totalTrials":50,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1835,"activeCount":54},[],{"trials":1837,"activeCount":54},[],{"trials":1839,"activeCount":54},[],{"trials":1841,"activeCount":54},[],{"trials":1843,"activeCount":54},[],{"trials":1845,"activeCount":54},[1846],{"nctId":1821,"briefTitle":1822,"status":153,"phases":1847,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":324,"conditions":1848,"interventions":1849},[47],[1827,1828],[1806,1830,1831],{"intervention":1831,"totalTrials":50,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1860,"NA":1862},{"trials":1853,"activeCount":54},[],{"trials":1855,"activeCount":54},[],{"trials":1857,"activeCount":54},[],{"trials":1859,"activeCount":54},[],{"trials":1861,"activeCount":54},[],{"trials":1863,"activeCount":54},[1864],{"nctId":1821,"briefTitle":1822,"status":153,"phases":1865,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":324,"conditions":1866,"interventions":1867},[47],[1827,1828],[1806,1830,1831],{"intervention":1869,"totalTrials":50,"cells":1870},"Inhaled anesthetics",{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1872,"activeCount":54},[],{"trials":1874,"activeCount":54},[],{"trials":1876,"activeCount":54},[],{"trials":1878,"activeCount":54},[],{"trials":1880,"activeCount":54},[],{"trials":1882,"activeCount":54},[1883],{"nctId":1884,"briefTitle":1885,"status":107,"phases":1886,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1891},"NCT01146431","Memory During Inhalation Anesthesia Performed With or Without Bispectral Index (BIS) in Patients Undergoing Thyroidectomy",[],"2010-06",130,[1890],"Thyroidectomy",[1869,1869],{"intervention":1893,"totalTrials":50,"cells":1894},"Nickel oral hyposensitization treatment",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1896,"activeCount":54},[],{"trials":1898,"activeCount":54},[],{"trials":1900,"activeCount":54},[],{"trials":1902,"activeCount":54},[],{"trials":1904,"activeCount":54},[],{"trials":1906,"activeCount":54},[1907],{"nctId":1908,"briefTitle":1909,"status":153,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1462,"enrollment":1913,"conditions":1914,"interventions":1917},"NCT03731494","Quality of Life in Systemic Nickel Allergy Syndrome",[],"2019-04-30","2019-05-30",52,[1915,1916],"Systemic Nickel Allergy Syndrome","Quality of Life",[1893],{"intervention":1919,"totalTrials":50,"cells":1920},"Sodium bicarbonate plus NAC",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1922,"activeCount":54},[],{"trials":1924,"activeCount":54},[],{"trials":1926,"activeCount":54},[],{"trials":1928,"activeCount":54},[],{"trials":1930,"activeCount":54},[],{"trials":1932,"activeCount":54},[1933],{"nctId":1934,"briefTitle":1935,"status":153,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1943},"NCT01218178","Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction",[],"2011-10","2008-06",520,[1941,1942],"Acute Myocardial Infarction","Acute Kidney Injury",[1919,1944],"Saline hydration plus NAC",{"intervention":1944,"totalTrials":50,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1948,"activeCount":54},[],{"trials":1950,"activeCount":54},[],{"trials":1952,"activeCount":54},[],{"trials":1954,"activeCount":54},[],{"trials":1956,"activeCount":54},[],{"trials":1958,"activeCount":54},[1959],{"nctId":1934,"briefTitle":1935,"status":153,"phases":1960,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":1939,"conditions":1961,"interventions":1962},[],[1941,1942],[1919,1944],{"intervention":1964,"totalTrials":50,"cells":1965},"3 mg drospirenone and 20 µg ethinyl-estradiol",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1967,"activeCount":54},[],{"trials":1969,"activeCount":54},[],{"trials":1971,"activeCount":54},[],{"trials":1973,"activeCount":54},[],{"trials":1975,"activeCount":54},[],{"trials":1977,"activeCount":54},[1978],{"nctId":1979,"briefTitle":1980,"status":153,"phases":1981,"primaryCompletion":294,"completion":294,"start":1982,"enrollment":502,"conditions":1983,"interventions":1985},"NCT01519401","Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.",[47],"2010-02",[15,1984],"Estro-progestin Drugs",[1964,1986],"3 mg drospirenone and 30 µg ethinyl-estradiol",{"intervention":1986,"totalTrials":50,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1990,"activeCount":54},[],{"trials":1992,"activeCount":54},[],{"trials":1994,"activeCount":54},[],{"trials":1996,"activeCount":54},[],{"trials":1998,"activeCount":54},[],{"trials":2000,"activeCount":54},[2001],{"nctId":1979,"briefTitle":1980,"status":153,"phases":2002,"primaryCompletion":294,"completion":294,"start":1982,"enrollment":502,"conditions":2003,"interventions":2004},[47],[15,1984],[1964,1986],{"intervention":2006,"totalTrials":50,"cells":2007},"ApoE",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":54},[],{"trials":2011,"activeCount":54},[],{"trials":2013,"activeCount":54},[],{"trials":2015,"activeCount":54},[],{"trials":2017,"activeCount":54},[],{"trials":2019,"activeCount":54},[2020],{"nctId":2021,"briefTitle":2022,"status":153,"phases":2023,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2031},"NCT03654911","Sustainable Method for Alzheimer's Prediction",[],"2019-06-28","2020-01-31","2018-04-11",150,[2029,2030],"Alzheimer Disease","Amnestic-Mild Cognitive Impairment",[2006],{"intervention":2033,"totalTrials":50,"cells":2034},"myo-inositol,alpha-lipoic acid and folic acid",{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2036,"activeCount":54},[],{"trials":2038,"activeCount":54},[],{"trials":2040,"activeCount":54},[],{"trials":2042,"activeCount":54},[],{"trials":2044,"activeCount":54},[],{"trials":2046,"activeCount":54},[2047],{"nctId":2048,"briefTitle":2049,"status":153,"phases":2050,"primaryCompletion":2051,"start":993,"enrollment":394,"conditions":2052,"interventions":2056},"NCT02651636","Combined Therapy With Myo-inositol and Alpha-Lipoic Acid in PCOS Women",[47],"2015-07",[15,2053,2054,2055],"Menstrual Pattern","Hyperandrogenism","Metabolic Features",[2033]]